Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)—Phase 1b results.

Caio Max S. Rocha Lima, Taofeek K. Owonikoko, Victor Priego et al.|Journal of Clinical Oncology|2017

Cited by 9